Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Elderly and Frail Patients With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® (ENDURANCE Trial)

NCT07821112 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT07821112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07821112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Elderly and Frail Patients With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® (ENDURANCE Trial)
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, elderly gbm, elderly glioblastoma, gbm, glioblastoma, glioma, glioma, malignant, oligodendroglioma